Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
27.05. | Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi | 2 | Investing.com | ||
27.05. | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | 263 | Newsfile | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
20.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
01.05. | Psyence Biomedical to execute 1-for-7.97 reverse stock split | 5 | Seeking Alpha | ||
01.05. | Psyence Biomedical kündigt Aktienzusammenlegung an | 6 | Investing.com Deutsch | ||
PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
01.05. | Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split | 247 | Newsfile | New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation... ► Artikel lesen | |
23.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
18.04. | Psyence BioMed gets Nasdaq notice for non-compliance | 1 | Seeking Alpha | ||
18.04. | Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 417 | Newsfile | New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April... ► Artikel lesen | |
15.04. | Psyence BioMed erhöht Beteiligung an PsyLabs mit 500.000 US-Dollar Investition | 2 | Investing.com Deutsch | ||
15.04. | Psyence BioMed boosts stake in PsyLabs with $500k investment | 2 | Investing.com | ||
15.04. | Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement | 247 | Newsfile | New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into... ► Artikel lesen | |
11.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
08.04. | Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia | 216 | Newsfile | New York, New York--(Newsfile Corp. - April 8, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the signing of a Letter of Intent (LOI) with Southern Star Research... ► Artikel lesen | |
31.03. | Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing | 186 | Newsfile | New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update:Dear Shareholders and Future Investors:At... ► Artikel lesen | |
31.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
25.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein | 1 | GlobeNewswire (USA) | ||
18.03. | Psyence Biomed expands advisory board with psychopharmacology expert | - | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
TRANSCODE THERAPEUTICS | 6,910 | -4,56 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
SILEXION THERAPEUTICS | 0,891 | +0,61 % | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
MINK THERAPEUTICS | 7,370 | -0,14 % | MiNK Therapeutics Announces Virtual Annual Shareholders Meeting | ||
BIONTECH | 92,00 | -0,22 % | BioNTech, Moderna und Co im Fokus: Kennedy greift durch | Nächster Paukenschlag in den USA: Gesundheitsminister Robert F. Kennedy Jr. hat alle Mitglieder eines Gremiums (ACIP) von Impfexperten der US- Seuchenbehörde CDC entlassen. Das geht aus einer Mitteilung... ► Artikel lesen | |
QIAGEN | 40,680 | -0,01 % | Qiagen NV-Aktie gewinnt 1,15 Prozent (40,805 €) | Im Wertpapierhandel liegt die Aktie von Qiagen NV gegenwärtig im Plus. Das Wertpapier kostete zuletzt 40,81 Euro. Für die Aktie von Qiagen NV steht gegenwärtig ein Wertanstieg 1,15 Prozent zu Buche.... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,920 | -4,84 % | HotStocks USA: TESLA, NVIDIA und RECURSION PHARMA stark gehandelt | ||
CUREVAC | 4,848 | +0,46 % | BioNTech SE: BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an | Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der... ► Artikel lesen | |
EVOTEC | 7,398 | -2,66 % | Aktie vor Turnaround?: Keine Geduld mehr mit Bayer und Evotec? Diese Aktie könnte die Lösung sein! | © Foto: Wolfgang Filser - picture alliance / SZ PhotoTurnaround-Wetten kosten viel Zeit, Nerven - und oft auch Geld. Vor allem Evotec und Bayer enttäuschten zuletzt immer wieder. Deutlich aussichtsreicher... ► Artikel lesen | |
DYNE THERAPEUTICS | 14,410 | -0,35 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 31,370 | -2,40 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,780 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
ARS PHARMACEUTICALS | 15,390 | +6,88 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
MODERNA | 23,180 | -1,19 % | Moderna Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
APOGEE THERAPEUTICS | 44,450 | +6,16 % | Apogee Therapeutics stock maintains buy rating ahead of key trial data |